-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] With the release of a series of domestic policies to promote pharmaceutical innovation and research and development, domestic pharmaceutical companies have begun to set off a wave of innovation
.
It is understood that since April this year, a large number of drugs have been approved for clinical use in China
.
For example, on April 21, the website of China's National Medical Products Administration (NMPA) announced that the new anti-tumor drug Procarbazine Hydrochloride Capsule (Natulan) submitted by Zhaoke Pharmaceutical, a subsidiary of Li's Pharmaceutical Factory, has been approved
.
According to an earlier press release issued by Lee's Big Pharma, the indication for this product's approved marketing application is: for the treatment of advanced Hodgkin's lymphoma
.
On April 20, Sino Biopharmaceutical announced that TQB2930, a class 1 new anti-tumor drug for injection, was approved for clinical trials for the treatment of patients with advanced malignant tumors
.
TQB2930 is a bispecific antibody targeting solid tumor cells, achieving synergistic effects against both targets
.
On April 19, the CDE website showed that Chia Tai Tianqing's Class 1 new drug TQH2722 injection was approved for clinical use and is intended to be used for the treatment of atopic dermatitis
.
Atopic dermatitis is a common chronic, relapsing, inflammatory skin disease with a highly heterogeneous and protracted course
.
It is worth noting that, in addition to the above-mentioned drugs, since 2022, Chia Tai Tianqing has 7 new category 1 drugs approved for clinical use
.
Among them, 5 new drugs including TQH2722 injection, TQB2930 for injection, TQB3915 tablets, TQH3910 tablets, and TQH3821 tablets were approved for clinical use for the first time
.
On April 15, Bio-Tech announced the clinical approval of BAT8009, an ADC drug targeting B7-H3
.
It is reported that on March 9, Bio-Tech announced that its other ADC drug, BAT8006, has also been approved for clinical use
.
The data show that BAT8006 is an ADC drug targeting FRα
.
In addition to the continuous approval of new drugs by a large number of pharmaceutical companies, many new drugs have also been successfully approved for marketing this year
.
For example, CSPC has 3 new products that have been approved for marketing, including lenvatinib mesylate capsules, mitoxantrone hydrochloride liposome injection, and duvelise capsules
.
Among them, lenvatinib mesylate capsules were approved in January this year
.
The data show that lenvatinib mesylate capsules is suitable for patients with unresectable hepatocellular carcinoma who have not received systemic therapy before, and it has been accepted as a first-line drug for the treatment of advanced liver cancer in China, Japan and the United States.
.
CSPC stated that the approval of this product will further enrich the Group's product portfolio and contribute to the Group's development in the anti-tumor field
.
In the same month, CSPC Doenda® (mitoxantrone hydrochloride liposome injection) was approved
.
The drug is used to treat relapsed or refractory peripheral T-cell lymphoma (PTCL)
.
It is reported that this is the independent research and development of CSPC, breaking the situation that China has not launched innovative drugs in the field of liposome drug research and development for many years
.
In addition, Duvelise Capsule was approved in March this year for the treatment of adult patients with relapsed or refractory follicular lymphoma (r/r FL) who have received at least two previous systemic therapies
.
The industry believes that with the active layout of pharmaceutical companies, domestic pharmaceutical innovation has clearly begun to enter a jump period from quantitative growth to qualitative improvement
.
In the future, in some fields, it may change from following and running to starting to lead
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
It is understood that since April this year, a large number of drugs have been approved for clinical use in China
.
For example, on April 21, the website of China's National Medical Products Administration (NMPA) announced that the new anti-tumor drug Procarbazine Hydrochloride Capsule (Natulan) submitted by Zhaoke Pharmaceutical, a subsidiary of Li's Pharmaceutical Factory, has been approved
.
According to an earlier press release issued by Lee's Big Pharma, the indication for this product's approved marketing application is: for the treatment of advanced Hodgkin's lymphoma
.
On April 20, Sino Biopharmaceutical announced that TQB2930, a class 1 new anti-tumor drug for injection, was approved for clinical trials for the treatment of patients with advanced malignant tumors
.
TQB2930 is a bispecific antibody targeting solid tumor cells, achieving synergistic effects against both targets
.
On April 19, the CDE website showed that Chia Tai Tianqing's Class 1 new drug TQH2722 injection was approved for clinical use and is intended to be used for the treatment of atopic dermatitis
.
Atopic dermatitis is a common chronic, relapsing, inflammatory skin disease with a highly heterogeneous and protracted course
.
It is worth noting that, in addition to the above-mentioned drugs, since 2022, Chia Tai Tianqing has 7 new category 1 drugs approved for clinical use
.
Among them, 5 new drugs including TQH2722 injection, TQB2930 for injection, TQB3915 tablets, TQH3910 tablets, and TQH3821 tablets were approved for clinical use for the first time
.
On April 15, Bio-Tech announced the clinical approval of BAT8009, an ADC drug targeting B7-H3
.
It is reported that on March 9, Bio-Tech announced that its other ADC drug, BAT8006, has also been approved for clinical use
.
The data show that BAT8006 is an ADC drug targeting FRα
.
In addition to the continuous approval of new drugs by a large number of pharmaceutical companies, many new drugs have also been successfully approved for marketing this year
.
For example, CSPC has 3 new products that have been approved for marketing, including lenvatinib mesylate capsules, mitoxantrone hydrochloride liposome injection, and duvelise capsules
.
Among them, lenvatinib mesylate capsules were approved in January this year
.
The data show that lenvatinib mesylate capsules is suitable for patients with unresectable hepatocellular carcinoma who have not received systemic therapy before, and it has been accepted as a first-line drug for the treatment of advanced liver cancer in China, Japan and the United States.
.
CSPC stated that the approval of this product will further enrich the Group's product portfolio and contribute to the Group's development in the anti-tumor field
.
In the same month, CSPC Doenda® (mitoxantrone hydrochloride liposome injection) was approved
.
The drug is used to treat relapsed or refractory peripheral T-cell lymphoma (PTCL)
.
It is reported that this is the independent research and development of CSPC, breaking the situation that China has not launched innovative drugs in the field of liposome drug research and development for many years
.
In addition, Duvelise Capsule was approved in March this year for the treatment of adult patients with relapsed or refractory follicular lymphoma (r/r FL) who have received at least two previous systemic therapies
.
The industry believes that with the active layout of pharmaceutical companies, domestic pharmaceutical innovation has clearly begun to enter a jump period from quantitative growth to qualitative improvement
.
In the future, in some fields, it may change from following and running to starting to lead
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
